RISK OF SERIOUS INFECTIONS ASSOCIATED WITH VEDOLIZUMAB VERSUS TUMOR NECROSIS FACTOR ANTAGONISTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A MULTINATIONAL, POPULATION-BASED COHORT STUDY

Julien Kirchgesner  1    
1 Brigham and Women's Hospital

Pathway
IBD, Immunology, Paediatrics, Primary Care


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing